Electrochemotherapy for Non-curable Gastric Cancer

Gastric Cancer Clinical Trial

Official title:

Electrochemotherapy for Non-curable Gastric Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04139070
• Other study ID #: REG-033-2019
• Status: Recruiting
• Phase: Phase 1
• Start date: June 15, 2020
• Est. completion date: July 1, 2021

Study information

• Verified date: August 2020
• Source: Zealand University Hospital
• Contact: Malene Broholm, MD
• Phone: 41272742
• Email: malea[@]regionsjaelland.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an explorative, phase I clinical trial. The aim of this study is to establish the safety and efficacy of electrochemotherapy for non-curable gastric cancer.

Description:

This is an explorative, phase I clinical trial. Aim of this study is to establish the safety of electrochemotherapy as a palliative treatment for advanced (non-curable) gastric cancer. The study involves recruitment of 8 patients with histologically verified and non-curable gastric cancer (including Siewert Type II and II). Patients will be recruited from Department of Surgery, Odense University Hospital and from Zealand University Hospital after their case has been reviewed by the multidisciplinary team (MDT). Electrochemotherapy will take place at Department of Surgery, Zealand University Hospital. After the treatment patients will be referred to Odense University Hospital for follow-up. Electrochemotherapy will be performed as an additive treatment to standard oncological care. Patients are treated once and will be followed with endoscopy, biopsies, scans, blood samples and questionnaires after 4-6 weeks and 8-12 weeks with a minimum interval of 4 weeks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 8
• Est. completion date: July 1, 2021
• Est. primary completion date: January 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must be mentally capable of understanding the information given.

• Patients must give written informed consent.

• Histologically verified gastric cancer (adenocarcinoma, including Siewert Type II and II)

• Non-curable disease according to MDT decision

• Age = 18 years.

• ASA class I-III (Classification of the American Society of Anesthesiology)

• Thrombocytes = 50 billions/l, INR >1,2. Medical correction is allowed, e.g. correction of elevated INR by means of vitamin K or administration of freshly frozen plasma.

• Performance status ECOG/WHO =2

Exclusion Criteria:

• Locally advanced non-metastatic EGJ/GC patients that may become resectable after pretreatment

• Inability to perform upper endoscopy with attached equipment.

• Uncorrectable coagulation disorder

• Patients with ICD or pacemaker units

• Myocardial insufficiency, defined as NYHA class >2

• Concurrent treatment with an investigational medicinal product.

• Renal impairment, defined as GFR <40 ml/min

• Pregnancy

• Concurrent inclusion in a medical trial where the intervention may affect safety measures used in the current protocol.

• Patients with any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study recruitments.

• Acute pulmonary infection.

• Medical history of severe pulmonary disease.

• Previous allergic reactions to bleomycin.

• Previous cumulative dose of bleomycin exceeding 250mg/m2.

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Bleomycin
Electroporation in combination with systemically administered bleomycin

Locations

Country	Name	City	State
Denmark	Department of Surgery, Zealand University Hospital	Køge

Sponsors (2)

Lead Sponsor	Collaborator
Zealand University Hospital	Odense University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events (CTCAE)	Safety evaluation will be performed via continuous assessment of safety parameters by reviewing events as they arise. The investigation will be put on hold if unacceptable safety issues are outstanding.; Adverse Events (AE) and Serious Adverse Events (SAE) will be evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE).	3 months
Secondary	Histopathological characterization of tumor biopsies	Endoscopic biopsies will be collected. Standard histology (Characterization of tumor tissue, fibrosis) will be performed and regression grade according to current standards	3 months
Secondary	Gene expression analysis	Specific immunohistochemical staining for PD-1/PD-L1, additionally, samples will be stained for CD3, CD8 and CD28. Finally, gene expression analyses will be performed using the Nano String method. In this current study, we plan to use the PanCancer IO 360 gene expression panel to analyze mRNA. This is a - 770-plex gene expression panel covering the complex interplay between tumor, microenvironment and immune response in cancer, including T and B cell activation and inhibition,, adhesion molecules, chemokines and cytokines, and pattern recognition receptors. This is a predefined gene panel and does not involve extensive mapping of the human genome.	3 months
Secondary	Quality of life with "The European Organization for Research and Treatment of Cancer quality of life questionnaire" (EORTC QLQ-C30)	Quality of Life questionnaires will be collected at baseline and after 8-12 weeks using the EORTC QLQ-C30 questionnaire. The questionnaire consist of 30 questions with a maximum score of 126 points and a minimum score of 30 points.	3 months
Secondary	Tumor volume	Tumor response will be evaluated through endoscopic ultrasound (EUS) to measure tumor volume before and after treatment	3 months